Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
doi: 10.1053/j.ackd.2014.11.004 38 MatsusakaTNiimuraFShimizuAPastanISaitoAKoboriHet al
Results of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, which compared dapagliflozin (10 mg once daily) to placebo, found that dapagliflozin was associated with a 44% reduction in a composite of adverse kidney outcomes and a 29% reduction in death from cardiovascular causes or hospitalization for heart failure
Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, et al
Table of Contents Key Takeaways: CJC-1295 is a Growth Hormone-Releasing Hormone (GHRH) analog that stimulates the pituitary gland to produce and secrete more natural growth hormone
Ultimately, these drugs may prove more effective in preventing cognitive decline or as part of combination therapies, but more research is needed before they can be recommended specifically for Alzheimers
Cramer expects the firms recently approved weight-loss pill (Foundayo) to help sustain its explosive growth rate
